Introduction {#Sec1}
============

Zellweger spectrum disorders (ZSDs, OMIM \#601539) constitute a subgroup of the peroxisome biogenesis disorders and represent a clinical continuum from severe to relatively milder phenotypes. ZSDs are caused by pathogenic mutations in at least 13 different *PEX* genes, encoding peroxins. Generally, there is genotype-phenotype correlation (Rosewich et al [@CR36]) (Moser [@CR27]). Patients with the severe phenotype present in the neonatal period with failure to thrive, jaundice, hypotonia and dysmorphic features (Weller et al [@CR47]) and high mortality within the first year of life. This severe phenotype was described as Zellweger syndrome (Bowen et al [@CR6]). Patients with a milder phenotype display a more variable symptomatology and age of presentation, but the onset is usually in early childhood. The most common presenting signs are developmental delay, with visual loss from retinal degeneration, sensorineural hearing loss and liver disease (Baumgartner et al [@CR3]). The majority of ZSD patients with a mild phenotype have normal MRI findings during childhood, but ultimately develop leukoencephalopathy later in life (Poll-The and Gärtner [@CR31]).

Definitive diagnosis requires laboratory investigations to assess peroxisomal functions, and confirmation by enzymatic analysis in fibroblasts, and/or PEX gene mutation studies.

Only limited data are available on the phenotype and natural history in adults with ZSDs (Rosewich et al [@CR36]) (Mignarri et al [@CR26]) (Matsui et al [@CR24]) (Raas-Rothschild et al [@CR33]) (Régal et al [@CR35]). To improve the accuracy of clinical diagnosis and to enable comparison of future evaluations of therapeutic interventions, we describe the natural history of a cohort of 19 patients (≥16 years) with molecularly defined ZSDs.

Material and methods {#Sec2}
====================

Patients {#Sec3}
--------

Retrospective clinical and laboratory data were collected from 19 ZSD patients. The diagnosis was confirmed by biochemical and molecular testing. Clinical and biochemical data were collected at many time points between 1991 and 2014. All patients were seen in the Academic Medical Centre in Amsterdam and examined by the authors (ME, PGB, or BTPT). Some data from patients 1, 3--6, 8, 13--14, 16--18 (Poll-The et al [@CR32]) and patient 4 (Ebberink et al [@CR12]) were reported previously. Age at diagnosis was defined as biochemically confirmed diagnosis, and not the onset of symptoms.

Hearing and visual assessment {#Sec4}
-----------------------------

Objective methods (brainstem audiometry evoked response and visually evoked potentials) and subjective methods (free-field audiometry and Snellen chart, with 1.0 scored as normal vision (Peters [@CR29])) were used to asses hearing and visual impairment.

Imaging {#Sec5}
-------

A total of 39 MRI studies of the brain were performed in 16 patients. The studies were performed on a 1.5 T MR scanner using the following sequences: axial, sagittal and coronal spin-echo T1-weighted, T2-weighted and axial fluid-attenuated inversion recovery image. The first MRI scans of patients 8, 9, and 16--19, the first and second MRI's of patients 1, 3, and 5 and the fourth MRI of patient 6 were described earlier (Barth et al [@CR2]). Liver cirrhosis was diagnosed using a Fibroscan, as described previously (Foucher et al [@CR19]).

Laboratory tests {#Sec6}
----------------

To establish whether a patient is affected by a ZSD several peroxisomal metabolites, reflecting the in vivo function of peroxisomes, were determined in blood, including levels of VLCFA, phytanic and pristanic acid (Vreken et al [@CR43]), pipecolic acid (Rashed et al [@CR34]) and bile acids (Bootsma et al [@CR5]). In erythrocytes, plasmalogen (C16:0- and C18:0-dimethyl acetal) levels were measured (Dacremont and Vincent [@CR8]) and levels of oxalic acid and glycolic acids were determined in urine spots and corrected for creatinine excretion (Wolthers and Hayer [@CR48]). A total of 332 biochemical analyses were performed in plasma, ranging from two (patient 4) to 43 (patient 18) tests per patient. Adrenal insufficiency was diagnosed by means of an adrenocorticotropic hormone stimulation (Synacthen) test (Berendse et al [@CR4]).

Several peroxisomal parameters were studied in cultured skin fibroblasts including, catalase immunofluorescence microscopy (Wanders et al [@CR44]), VLCFA profile (Dacremont et al [@CR9]), peroxisomal alpha- and beta-oxidation activity (Wanders et al [@CR45]) and dihydroxyacetonephosphate-acyltransferase (DHAPAT) activity (Wanders et al [@CR46]).

Mutation analysis {#Sec7}
-----------------

Complementation analysis in cultured skin fibroblasts was used to determine the defective *PEX* gene, followed by Sanger sequencing on genomic DNA (Ebberink et al [@CR11]).

Statistical analysis {#Sec8}
--------------------

Mann--Whitney U tests were performed using the IBM Statistical package for the Social Sciences (SPSS) software version 20 (IBM, U.S.A.).

Standard protocol approvals, registrations and patient consents {#Sec9}
---------------------------------------------------------------

For this project the IRB issued a waiver since the study is retrospective and only anonymized data was used. Written informed consent was obtained from the parents of all the patients, and authorization for disclosure of recognizable persons in photographs for publication were obtained.

Results {#Sec10}
=======

The detailed clinical characteristics of the 19 patients from 16 families are summarized in Tables [1](#Tab1){ref-type="table"} and [2](#Tab2){ref-type="table"}. All patients, nine females and ten males, were of Caucasian background and no parental consanguinity was reported. To obtain a framework for comparing the severity of the neurologic disorder with the MRI findings and biochemical abnormalities we delineated two broad categories on the basis of the degree of communication. Patients in group 1 (patients 1--12) were able to communicate with structured grammatical speech and patients in group 2 (patients 13--19) had no structured speech. Age at diagnosis varied between 7 days and 31 years (mean group 1: 7.6 years, group 2: 1.2 years). The diagnosis of patients 3 and 16 was at an early age because they had an affected older sibling. In two other patients (2 and 4) there was a significant delay before diagnosis, due to normal peroxisomal metabolites in plasma and a clinical presentation atypical for a ZSD (Ebberink et al [@CR12]).Table 1Clinical and genetic characteristics of 19 ZSD patients (group 1: patients 1--12; group 2: patients 13--19)No. 1(A)No. 2No. 3(A)No. 4No. 5No. 6No. 7No. 8(B)No. 9(B)No. 10No. 11No. 12No. 13(C)No. 14No. 15No. 16(C)No. 17No. 18^a^No. 19Mutations Allele 1P1c.2528G\>P1c.2528G\>AP1c.2528G\>AP11Bc.64C\>TP26c.292C\>TP1c.2528G\>AP1c.1777G\>AP1c.2528G\>AP1c.2528G\>AP6c.1801C\>TP1c.2528G\>AP26c.292C\>TP1c.2528G\>AP1c.2528G\>AP1c.2528G\>AP1c.2528G\>AP1c.2528G\>AP1c.2528G\>AP1c.2528G\>A Allele 2P1c.2528G\>P1c.2528G\>AP1c.2528G\>AP11Bc.64C\>TP26c.292C\>TP1c.2528G\>AP1c.2071+1G\>TP1c.2528G\>AP1c.2528G\>AP6c.1992G\>CP1c.2528G\>AP26c.292C\>TunknownP1c.2528G\>AP1c.2528G\>AunknownP1c.2636 T\>CP1c.2097insTP1c.2528G\>A Age at latest visit (yrs)35323127.5232219.51917.517.51716282724.52218.51817 Age at diagnosis (yrs)5310.2525620.253.533840.50.750.020.021.30.55Presenting symptoms Failure to thrive+++++ Bilateral 4-fingerline+++ Hearing impairment++++++++ Hypotonia++++ Jaundice+++++++ Visual impairment++++++++++++Facial dysmorphia Attached earlobes++++++++++++ Epicanthal folds+++ High forehead++++++Speech development Absent++++++ Short sentences+++ Sufficient working vocabulary++++++++++Intellectual disabilitymoderatemoderatemoderatemoderatemoderatemoderatemoderatemoderatemoderatemoderatenonemoderatesevereseveresevereseveresevereseveresevere Age of examination in yrs73218111556149159159 Total IQ54676460 Verbal IQ\<555467105 Non-verbal IQ60545983 Developmental level in yrs2.572.512Residence Assisted living facility+++ Parental home++++++++ Parental home with continuous supervision+++++nursing home+++Education Higher vocational education+ Sec. vocational education level 1^b^++ Special education cluster 2^c^++++++ Special education cluster 3^d^+++Supported employment ^e^+++++++MiscellaneousEHEHEHEHEHEH, explicit memory at a normal levelEHEH, able to cope with money, drives a scooterEH, drives a bicycleEHEH, completely normal gaitEH, able to cope with moneyEHEH, examined during house callEHEH, PEG tube (at 7 years of age)EHEH, PEG tube (at 5 years of age)EH*Abbreviation: EH* enamel hypoplasia, *P* PEX, *IQ* intelligence quotient, *PEG* percutaneous endoscopic gastrostomy(A) sibs; (B) sibs; (C) sibs^a^Patient died at 18 years^b^Education for specific trades or occupations, ascending difficulty of access criteria from level 1 to 4^c^School for deaf and partially hearing children, or children with serious speech and language difficulties^d^School for children with serious learning difficulties, long-term condition and somatic problems, physical handicap and a physical handicap^e^Paid work for mentally or physically disabled persons, taking place in regular or normal work settings, with continuous supervisionTable 2Clinical characteristics of 19 ZSD patients (group 1: patients 1--12; group 2: patients 13--19)Nervous systemNo. 1 (A)No. 2No. 3 (A)No. 4No. 5No. 6No. 7No. 8 (B)No. 9 (B)No. 10No. 11No. 12No.13(C)No. 14No. 15No. 16 (C)No. 17No. 18^a^no. 19Visual system Cataract++ Retinitis pigmentosa++++++++++++++++ Visual acuity scales^b^0.330.050.080.10.110.10.10.20.250.250.250.150.20.050.04\<0.10.10.05 Stable/progressive=↓↓↓============↓=VEP, age at examination in yrs3026182141341111151 FlashnormalPLPLnormalPLDLPLPLPLpoor pattern PatternPLPLPLDLDLPLHearing systemCI Hearing loss (dB),left/right8090/11080/7580857090/908095impossible to asses Low frequency6080754080 High frequency110807511080 Stable/progressive===↓↓======↓====BAEP, age at examination in yrs30261814131111212 Absent++++++++ Normal++Motor and sensory systemCS, PSPNCS, PN, PSCS, PSCSCS, PNCS, PNCSPNPSCS, PNPSCS, PN, PS Ataxia+++++++ Babinski+++++ Brisk reflexes++++++ Clonus++ Dysarthria++++ Dysmetria++++ Intention tremor++ Nystagmus++++++++ Absent reflexes++ Clawfeet+ Contractures ankles/knee++ Hammertoes++++ Muscular atrophy+++++++ Pes cavus+++++++ Other signsabsent vibration sensesteppage gaitunable to walkno reaction upon pain stimuliNCS, age at examination in yrs30161814114 Normal++++ Sensory responses Demyelinating PN++Other systemic featuresLCLCLFAI, HM, KS, LC, SMMaximal motor skills Wheelchair-bound++++++ Sitting+++ Walking with support++ Walking+++ Running+++++++++++Disease course in recent years===↓↓↓==↓======↓↓↓↓↓=Clinical deterioration/age in yrsPN/26ataxia/15ataxia/16in MF/16in MF/12in MF/16in MF/14*Abbreviation: AI* adrenal Insufficiency, *BAEP* brainstem acoustic evoked potentials, *CS* cerebellar syndrome, *DL* delayed latency, *HM* hepatomegaly, *KS* kidney stones, *LC* liver cirrhosis, *LF* liver fibrosis, *MF* motor function, *NCS* nerve conduction studies, *PL* prolonged latency, *PS* pyramidal signs, *PN* polyneuropathy, *VEP* visually evoked potentials, *SM* splenomegaly"=" = stable; ↓ = slowly progressive; ↓↓ = progressive(A) sibs; (B) sibs; (C) sibs^a^Patient died at 18 years^b^Tests are expressed as Snellen equivalent

We obtained information about clinical features, biochemical profile, education, current level of social functioning and help required for activities of daily living.

Clinical features {#Sec11}
-----------------

During infancy, seven of the 19 patients had prolonged neonatal jaundice, four presented with hypotonia, five with failure to thrive, 12 had a visual handicap due to retinal degeneration and eight patients presented with hearing impairment (Table [1](#Tab1){ref-type="table"}). During childhood, all patients had a moderate to severe developmental delay as well as visual and hearing loss. Current ages ranged from 16 to 35 years (mean 22.5 years). Patient 18 died from liver failure at 18 years. At last follow-up, all patients had nyctalopia and retinopathy, caused by retinitis pigmentosa in 16/19. Visual acuity ranged from 4 to 33 % (mean 14 %) with 100 % being normal vision and 5 % defined as legally blind in Europe (Kocur and Resnikoff [@CR22]). The visual impairment was progressive in four and stable in 14 patients. All had gross sensorineural hearing deficits, ranging from a loss of 60 dB to 110 dB and 17 patients (except patients 15 and 18) used hearing aids with clinical benefit. Ambulation ranged from running (11/19) to walking unsupported (3/19), walking with support (2/19) and the ability to sit unsupported (3/19). Patient 5 had normal motor function during childhood. However, since the age of 15 years he lost the ability to walk independently due to progressive cerebellar ataxia and weakness caused by peripheral neuropathy. At the age of 21 he developed pyramidal signs and became completely wheelchair-bound at 23 years. Patient 18 was able to walk independently at 4 years of age, but at the age of 14 years she developed progressive cerebellar and sensory ataxia and lost independent ambulation.

Specific findings included cerebellar signs in 9/19, pyramidal signs in 5/19 and signs of peripheral neuropathy in 11/19 patients (Table [2](#Tab2){ref-type="table"}). The peripheral neuropathy could only be confirmed by nerve conduction studies in two patients (5 and 10), due to reluctance of the parents to allow latter studies. In these two patients the neuropathy was classified as a demyelinating neuropathy, according to established criteria with a motor conduction velocity below 41 ms in the median nerve and 35 ms in the peroneal nerve (Van Asseldonk et al [@CR40]). Overall, seven had progressive neurological symptoms (mainly worsening of the gait disorder) and 12 were stable at most recent follow-up. Epilepsy was not seen in any of the patients.

Non-neurological findings included splenomegaly, hepatomegaly, renal pelvic stones and adrenal insufficiency in one patient and liver cirrhosis in 3/19. All patients had enamel hypoplasia.

Activities of daily living {#Sec12}
--------------------------

Of the 19 patients, six lived in assisted-care facilities (Table [1](#Tab1){ref-type="table"}), of whom patients 15 and 17--18 lived in a round the clock care facility and were completely dependent on others (i.e., nursing home). The remaining three were self-supporting with respect to daily life activities, albeit under supervision. The other 13 patients lived with their parents, with or without continuous supervision. Of these patients, only patients 13 and 14 were not able to feed themselves independently. All patients except for patient 11 had a minor to severe gait disorder, limiting their physical mobility. Cognition varied widely from normal cognitive abilities in patient 11, to moderate or severe intellectual disability in most.

MRI findings {#Sec13}
------------

Cerebral MRI scans were available from 16 patients, with follow-up in 10 (Table [3](#Tab3){ref-type="table"}). T2-weighted MR images showed progressive hyperintense white matter changes in the cerebral hemispheres in 4/16. These were located around the supratentorial ventricular system merging with surrounding normal white matter without sharp demarcation. Patient 6 (Fig. [1](#Fig1){ref-type="fig"}) had additional lesions in the corpus callosum and in the posterior limbs of the internal capsules. Follow-up images showed progressive central cerebellar white matter changes on T2-weighted images between 11 and 22 years. Furthermore, 8/16 patients had T2 hyperintensities in the areas surrounding the cerebellar dentate nuclei, which was progressive in 3 (patients 3, 5--6). T2-hyperintensity in the cerebellar white matter was seen in 6 patients, and was progressive in one (patient 6). Two patients (16, 18) had supratentorial ventricular dilatation and 6/16 presented with cerebellar cortical atrophy, of whom 3 patients (3, 16, 18) showed concomitant supratentorial cortical atrophy.Table 3Brain magnetic resonance imaging characteristics in 19 ZSD patientsPatients no.Age at MRI, yrsWhite matter hyperintensity^a^Cerebellar cortical atrophyCerebral hemispheresCerebellumHDNWM114────21────30────232─+ ++ +─310────16+++─25+ ++ +++412────57─+++13─+++21─+++++60.5────2────4─+──11+ ++ +──14+++++++─17++++++++++─18+++++++++++++─22++++++++++++++─714────84────13─+─+17─+─+93────6────13++++++─16++++++─10none113────15────126─+──11─+──16─+──13none14none151────167───+177++──181────17──++193────9───+*Abbreviation: HDN* hilus of the dentate nucleus, *WM* cerebellar white matter"−" = absent; "+" = The number of plus signs indicates disease severity^a^T2-weighted imagesFig. 1**a**--**c** Growth, development, brain MR images and biochemical parameters of patient 6. **a** At the age of 2 and 4 years patient 6 was completely normal and only presented a mild developmental delay and visual impairment. Since the age of 16 years, a decline in disease progression was noted and this patient developed progressive pyramidal tract symptoms with a gait ataxia. **b** Leukoencephalopathy with slowly progressive disease course. Axial T2-weighted MR images at level of cerebellar dentate nuclei and cerebellar white matter show bilateral progressive white matter hyperintensities of the hilus of the dentate nucleus and central white matter of both hemispheres between 4 and 22 years old. MR images at 2 years old were normal. **c** Fluctuations of the biochemical parameters measured in plasma at different time points, which are representative for the other patients. Note that both DHCA and THCA were normal at the age of 15 years but abnormal at 21 years. The reference range of pipecolic acid is 0.1--7 μmol/l, of THCA 0.0--0.1 μmol/l and of C26:0 0.45--1.32 μmol/l. The levels of DHCA are not detectable in controls. **d** Boxplot showing median, interquartile range, minimal and maximal range of the average level of DHCA, THCA, C26:0 (all *left axis*) and pipecolic acid (*right axis*) in plasma per patient throughout life between group 1 (*white* and *white dotted bars*) and 2 (*gray* and *gray dotted bars*). A total of 332 biochemical analyses were performed, ranging from 2 (patient 4) to 43 (patient 18) tests per patient. Statistical analyses were performed with a Mann--Whitney *U* test. *Abbreviation: ns*, not significant

Laboratory tests {#Sec14}
----------------

Detailed individual biochemical profiles, during the time of diagnosis and last follow-up, are described in Tables [4](#Tab4){ref-type="table"} and [5](#Tab5){ref-type="table"}. At the last available measurement the most important abnormalities in plasma included elevated levels of C26:0 (16/19 patients), pipecolic acid (10/19 patients), DHCA (9/19 patients) and THCA (6/19 patients). There were two patients (patients 2 and 11) with only one mildly abnormal peroxisomal biomarker in plasma and erythrocytes. Compared with the biochemical results at time of diagnosis, we observed a decline in the levels of DHCA and THCA (15/19 patients), C29-dicarboxylic acid (13/14 patients) and pipecolic acid (10/19 patients), and in some patients even a complete normalization (patients 6--11, 14, 19).Table 4Biochemical Analyses in plasma, erythrocytes and urine from ZSD patientsPatient 1 (A)Patient 2Patient 3 (A)Patient 4Patient 5Patient 6Patient 7Patient 8 (B)Patient 9 (B)Patient 10Patient 11Patient 12Patient 13 (C)Patient 14Patient 15Patient 16 (C)Patient 17Patient 18Patient 19Age, yrsRef. range12^a^35^b^31^a^33^b^8^a^31^b^26^a^27.5^b^8^a^23^b^1.6^a^23^b^4^a^19.5^b^4^a^19^b^4^a^17.5^b^3.5^a^17.5^b^8^a^17^b^5.5^a^16^b^11.5^a^28^b^8.5^a^18^b^birth^a^24^b^1^a^22^b^1.5^a^16^b^0.5^a^18^b^5^a^17^b^Plasma C22:0, μmol/l40-119**14**26.25172.5**9.638.2**6553.34**3627.412.1**77.1**1834.59**54.5**31.6**42.78**17.2**40.1846.861.7**1620.3**45.856.4**19.73819**94.2**10.531.61532.2**76**22.729**49.6 C24:0, μmol/l33-8437**45**57.3**44.3**75.648.837**29.517.1**78.8**21**39.933457.940.248.31**18.2**37.8447.458.9**1425.2**44.565.54539**32**84.1**19.729.322**34.533.93954.8 C26:0, μmol/l0.45--1.320.5**3.312.2**0.730.51.161.3**1.3842.732.783.511.51.671.81.633.012.351.631.331.91**1.28**1.471.432.644.721.381.92.82.443.152.45.63.16**0.89**4.633.34.17** C26:0/C22:0, ratio0--0.02**0.040.130.04**0.01**0.050.05**0.02**0.030.110.10.230.050.080.050.030.10.050.10.030.04**0.02**0.090.070.060.080.070.050.150.030.30.080.360.1**0.01**0.20.110.08** CA, μmol/l0.1--4.70.80.80.60.11.72.61**10.7**0.51.50.12.910.821.20.4**6.7**0.31.91.42.60.81.71.43.61.5**10.9**1.42.51.5**3248.26.3**0.6 CDCA, μmol/l0.7--102.63.620.60.60.20.34.21.3**12**0.30.45.43**11.5**4.11.53.30.6104.80.40.20.70.62.80.63.31.58.46.85.58.2**14**0.9 DHCA, μmol/l0**0.21.6**00**0.20.3**00**103.10.5**0**6.1**0**1.1**0**0.6**0**0.9**0**0.4**0**22.42.82.30.10.1**0**0.30.12.91.262.2474.51.2**0 THCA, μmol/l0--0.1**0.20.9**00**0.3**0.100**1.91.20.4**0**6.2**0**0.6**0.1**0.3**0.1**1.7**0.1**1.9**0**15.17.21.8**0.10.10.1**10.30.19.50.23.51.13347.42.2**0 C29, μmol/l0**0.1**0000**1.70.20.3**0**1.2**0**1.2**0**0.1**0**0.1**0**0.1**0**0.40.10.9**000**4.4**0**2.30.1250.30.3**0 Pipecolic acid, μmol/l0.5--9.9**10.820.4**3.51.41.8**38.6500**2.9**111**33.7**13.7**7.6**33.610.210.5**5.5**36.146.115.83221.4**3.3**14.1**2.9**14.728310.723053.32713** Pristanic acid, μmol/l0.1--32.6**4.3**2.90.2**5.5**0.90.60.5**267.7**0.820.3**21**0.6**3.2**1.501.1**16.6**0.1**16.715.965.4**0.20.420.8**44**2.92.60.4**9.77.9** Phytanic acid, μmol/l0.1--7**4.4106.6**2.2**8.4**1.24.64**9827.6**14.2**14**1**49**4.5**117.410**3.2**36.1**0.9**68.855.97725.4**3.51.125.92.66.3**17011.57.9**3.9**3013** AST, U/L^c^23352429243055**58**387730**58**31**62**2933**60**24**50**28**594397**30**121**23**4754585458**36 ALT, U/L^d^2725293317**48124**3440**56**27**27**20273016172514**48**18353425**50**34**74**20263537162531 Gamma-GT^e^27**55**1852222830183119181471416232860175831**45**Erytrocytes C16:0 DMA6.8--11.9 %7.9**6.2**6.886.9**4.95.7**8.29.2**1.5**7.37.37.68.4**6.3**7.67.59.6**6.4**7.5**6.5**7.77.29.47.98.7**6.74.3**8.3**6.56.65.2**87.3 C18:0 DMA10.6--24.9 %1614.718.81615.81212.21822.4**7.9**19.61715.52115.417.917.718.317.12016.317.917.121.219.91716.8**9.3**1815.311.3**10.1**1719.4Urine ^f^ Oxalic acid0.02--0.06**0.060.06**0.050.020.040.010.110.01**0.16**0.02**0.1**0.04**0.09**0.030.06**0.080.150.1**0.04 Glycolic acid20--140115120139601245819910234**261209**118**266356**70126**286231***Abbreviation: AST* aspartate aminotransferase, *ALT* alanine aminotransferase, *CA* cholic acid, *CDCA* chenodeoxycholic acid, *DHCA* dihydroxycholestanoic acid, *DMA* dimethyl acetal, *THCA* trihydroxycholestanoic acid(A) sibs; (B) sibs; (C) sibsAll the results outside the reference range are depicted in bold^a^Age at first (complete) biochemical analysis^b^Age at last complete biochemical analysis^c^♂/♀0--40, 0--1 year: 0--95; 1--3 years: 0--60^d^♂0--45, ♀0--34; 0--1 year: 0--65^e^♂0--60, ♀0--40; 1--15 year 0--56^f^Oxalic acid: mmol/mmol creatinine, glycolic acid: mmol/mol creatinineTable 5Biochemical analyses in cultured skin fibroblasts from ZSD patientsRef. rangeNo. 1 (A)No. 2No. 3(A)No. 4No. 5No. 6No. 7No.8 (B)No. 9 (B)No. 10No. 11No. 12No.13 (C)No. 14No.15No.16 (C)No.17No. 18No. 19Fibroblasts C22:0, μmol/g protein3.84--10.20**3.022.76**5.47**2.363.35**4.67**3.013.6**4.175.18**3.332.92.73**5.45**2.913.68** C24:0, μmol/g protein7.76--17.66**7.68**8.811.04**5.41**8.748.6413.1611.169.5914.148.468.66**6.12**12.488.3710.64 C26:0, μmol/g protein0.18--0.38**0.761.25**0.27**1.230.980.563.082.520.961.450.41.350.771.691.721.73** C26:0/C22:0, ratio0.03--0.07**0.250.45**0.05**0.520.290.121.020.70.230.280.120.470.280.310.590.47** C26:0β-oxidation, pmol/(h\*mg protein)1214--1508**424**2069**21348283658172248939911187143226713317** Pristanic acid β-oxidation, pmol/(h\*mg protein)675--1121**9**736**5727107171131376143017832118117** Phytanic acid α-oxidation, pmol/(h\*mg protein)44--82**406413811731381** DHAPAT activity, nmol/(2 h\*mg protein)5.8--12.3**1.23.5**12**1.524.34.82.83.3**6.28.4**1.722.90.721.622.5**Catalase immunofluorescencepunctatemosaicmosaicpunctateenlargedmosaicenlargedenlargedenlargeddiffusemosaicdiffusediffuseenlargeddiffuse*Abbreviation: DHAPAT* dihydroxyacetonephosphate-acyltransferase, *diffuse* cytoplasmic catalase distribution, *punctuate* peroxisomal catalase distribution, *mosaic* both fibroblasts with diffuse and punctuate distribution, *enlarged* less peroxisomes and enlarged in sizeControl fibroblasts show a punctuate catalase distribution, as catalase is imported into functional peroxisomes(A) sibs; (B) sibs; (C) sibsAll the results outside the reference range are depicted in bold

In general, patients had reduced levels of fat soluble vitamins (A, D, E and K) and a coagulopathy, due to a combined vitamin K malabsorption and liver dysfunction. The majority of patients had a low-phytanic acid and low-fat diet and 14 patients received vitamin A, D, E and K supplementation.

Discussion {#Sec15}
==========

The ZSDs have long been considered lethal in infancy or early childhood, based on the original description of Zellweger syndrome (Bowen et al [@CR6]). In this retrospective study, we describe a large cohort of patients with a ZSD and show that the natural history is highly variable with a distinct subgroup surviving well into adulthood. The phenotypic spectrum is therefore much wider, with implications for counseling of patients and their families.

We attempted to identify clinical, biochemical, genetic and/or MRI characteristics typical for this subgroup with long survival. We divided the patients in this cohort into two categories based on the degree of communication. Patients in group 1 (patients 1--12) were able to communicate with structured grammatical speech and patients in group 2 (patients 13--19) did not achieve structured speech. The correlation between the phenotype and genotype, at least with respect to the mild *PEX1* c.2528G\>A and *PEX26* c.292C\>T mutation in its homozygous form versus the more severe compound heterozygosity (*PEX1* c.2097insT+*PEX1* c.2528G \> A), which was described previously (Rosewich et al [@CR36]) (Bader et al [@CR1]), was also seen in our study.

In previous case reports, age at first symptoms varied from 3 to 12 years and age at diagnosis varied from 10 to 51 years (Rosewich et al [@CR36]) (Mignarri et al [@CR26]) (Matsui et al [@CR24]) (Raas-Rothschild et al [@CR33]) (Régal et al [@CR35]). The average age at diagnosis in our cohort was at a much earlier age of 5.2 years. Hence, we had the possibility to monitor the clinical and biochemical spectrum over a relatively long period of time.

Hearing impairment, an important characteristic of ZSD patients (Moser et al [@CR28]), was not reported in some of the mild adult patients described in previous reports (Régal et al [@CR35]) (Sevin et al [@CR37]) (Steinberg et al [@CR39]), but all patients in our cohort had impaired hearing and vision. The predominant neurological symptom in the adult patients is a gait disorder, caused by combinations of a cerebellar syndrome, pyramidal tract dysfunction and peripheral neuropathy. Unexpectedly, we observed a high prevalence of signs of peripheral neuropathy in adolescence/adulthood (11/19), especially in group 2 (6/7), while none of these patients presented these symptoms in childhood. The majority of patients was diagnosed with a peripheral neuropathy on clinical grounds. Confirmatory nerve conduction studies, however, were only performed in two patients, which is a limitation of our study. As reported previously (England et al [@CR15]), the combination of signs and symptoms have a relatively good accuracy for diagnosing a peripheral neuropathy. It is noteworthy that two patients developed a demyelinating peripheral neuropathy. This contrasts with another peroxisomal disease, X-linked adrenoleukodystrophy, in which axonal rather than a demyelinating peripheral neuropathy is usually present (van Geel et al [@CR41]) (Engelen et al [@CR14]) (Chaudhry et al [@CR7]).

Previous MRI studies showed progressive cerebral demyelination in peroxisome biogenesis disorder patients with a mild phenotype, mostly in the cerebellum, brainstem, posterior limb of the internal capsule and posterior cerebral white matter (Barth et al [@CR2]). In this study, the major MRI abnormalities (i.e., white matter hyperintensities) were found in the central white matter of both cerebellar hemispheres and/or areas surrounding the dentate nuclei on T2-weighted images (9/16). These lesions can also be found in patients with D-bifunctional protein deficiency, an isolated peroxisomal β-oxidation defect, with prolonged survival (i.e., \>7.5 years) (Ferdinandusse et al [@CR17]). Normal MRI was found in five patients. Symptomatic leukoencephalopathy was present in seven patients (2, 5--6, 9, 12, 17--18) and silent leukoencephalopathy in two (3, 8). Overall, individuals in both groups presented similar findings on MRI ranging from normal findings to leukoencephalopathy.

Liver dysfunction is a common feature in ZSD patients. However, in this cohort only four patients (in group 2) had liver cirrhosis/fibrosis. The prevalence of hyperoxaluria (2/14) and hyperglycolic aciduria (3/13) was much lower than previously reported in ZSD patients older than 1 year (van Woerden et al [@CR42]). Only patient 18 suffered from nephro- and urolithiasis.

In our cohort 12 patients were clinically stable in recent years and seven showed a progressive disease course. The disease progression becomes apparent in adolescence (age 12--16 years), with gait disturbance being the most prominent symptom (in 7/7).

Seventeen of the 19 patients had a typical ZSD biochemical phenotype in blood at the time at diagnosis. At latest follow-up we observed normal blood levels of several peroxisomal biomarkers in patients (Table [4](#Tab4){ref-type="table"}). Normal levels of some parameters have already been reported by others (Sevin et al [@CR37]) (Ebberink et al [@CR10]). Importantly, our study is the first to show a decline in the levels of these metabolites with age and in some patients even a complete normalization. In particular the levels of DHCA, THCA, and pipecolic acid were found to decline during life and they eventually normalized. In some patients we noted a decrease in these parameters as well as in liver enzymes. This suggests that improved liver function might play a role in the decrease of these metabolites, as they are predominantly synthesized in the liver (Ferdinandusse and Houten [@CR16]). However, there were also patients with normal liver function and elevated levels of abnormal peroxisomal metabolites in childhood. In these patients we also observed a decline in these peroxisomal parameters, meaning that this decline cannot be entirely attributed to normalization of liver functions. The decline in DHCA and THCA levels may also be caused by a decreased synthesis of bile acids with increasing age (Einarsson et al [@CR13]). Furthermore, we observed strong fluctuation of several parameters in the majority of the patients. The concentration of peroxisomal metabolites can fluctuate between normal and abnormal (Fig. [1](#Fig1){ref-type="fig"}). Overall, the diagnosis ZSD would be missed in two patients (2 and 11) at last follow-up and in patient 4 at first analysis based on the C26:0, bile acid levels, pristanic- and phytanic acid concentrations in plasma.

Our data suggest that a ZSD cannot be excluded by biochemical testing in plasma alone, and that in some individuals (i.e., patient 2, 4, and 11) a complete analysis in skin fibroblasts (including culturing fibroblasts at 40 °C (Ebberink et al [@CR12])) is indicated if clinical suspicion is high. Skin fibroblast examination is also necessary to discriminate between a ZSD or a single-enzyme deficiency, which is diagnosed in at least 15 % of the individuals presenting with a ZSD clinical phenotype (Steinberg et al [@CR38]). Recently, D-bifunctional protein-deficiency has been identified by whole-exome sequencing in seven adults without detectable biochemical abnormalities in blood (Pierce et al [@CR30]) (McMillan et al [@CR25]) (Lines et al [@CR23]). Because of considerable overlap between Usher syndrome and milder ZSD phenotypes, i.e., the combination of deafness and retinitis pigmentosa, individuals suspected to have Usher syndrome should be screened for peroxisomal dysfunction (Raas-Rothschild et al [@CR33]).

Efforts to correlate biochemical, cellular, and molecular characteristics of ZSD patients to their clinical outcome, mainly in terms of survival, have provided valuable information. Gootjes et al suggested that DHAPAT and C26:0 β-oxidation activity are predictors of survival in patients with a ZSD. However, these measurements in cultured skin fibroblasts could only be used to roughly predict survival of \<1 year or \>5 years (Gootjes et al [@CR20]). Despite these associations, prediction of prognosis remains challenging and is influenced by many other variables (e.g., quality of supportive care). We evaluated how the parameters of peroxisomal dysfunction relate to disease severity and long-term progression. We noticed higher levels of abnormal peroxisomal metabolites (e.g., DHCA, THCA, and C26:0) in group 2 during childhood, but there were no differences in adulthood. Concentrations of pipecolic acid were higher in those patients with a progressive disease course. Patients in group 2 had higher levels of C26:0 in plasma than patients in group 1 throughout life (Fig. [1d](#Fig1){ref-type="fig"}). Ferdinandusse et al reported that C27-bile acid intermediates (DHCA/THCA) induce apoptosis, decrease cell viability and are more toxic than C24-bile acids (Ferdinandusse et al [@CR18]). It is noteworthy that the most severely affected patient (18) had extremely high plasma levels of DHCA and THCA ranging from 50 to 130 μmol/l in the first year of life. The patients with a less severe phenotype presented with DHCA and THCA levels of approximately 10 and 2 μmol/l, respectively. However, on the basis of the present study, we were unable to identify a correlation between the concentration of abnormal peroxisomal metabolites, skin fibroblast data and the severity of the clinical phenotype or progression of the disease. The metabolites measured in plasma probably do not reflect the level of accumulation in organs. This suggests that the wide spectrum of clinical presentations may be related to varying amounts of residual peroxisomal enzymatic activities in target tissue. Further studies are therefore required to determine the precise role of the peroxisomal biomarkers in the pathogenesis of ZSDs. The recently constructed PEX1 mouse model (Hiebler et al [@CR21]) may be a valid model to study these relations.

In summary, we describe the natural history of a cohort of ZSD patients who reached adulthood and represent a distinct subgroup within the ZSDs. A high percentage of patients show pyramidal symptoms with or without peripheral neuropathy. Some patients with prolonged survival present an insidiously progressive disease course, despite normalization of biomarkers for peroxisomal disease measured in plasma and erythrocytes. This study emphasizes that ZSDs should no longer be considered solely as a paediatric disease, but rather as a slowly progressive disease with patients surviving into adulthood. This study is important for the interpretation of future therapeutic trials and for those involved in the clinical care of adult patients.

DHAPAT

:   dihydroxyacetonephosphate-acyltransferase

DHCA

:   dihydroxycholestanoic acid

DMA

:   dimethyl acetal

THCA

:   trihydroxycholestanoic acid

VLCFAs

:   very long-chain fatty acids

ZSDs

:   Zellweger spectrum disorders
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